ATE402267T1 - Verfahren zur herstellung von monoklonalen antikörpern - Google Patents
Verfahren zur herstellung von monoklonalen antikörpernInfo
- Publication number
- ATE402267T1 ATE402267T1 AT00912975T AT00912975T ATE402267T1 AT E402267 T1 ATE402267 T1 AT E402267T1 AT 00912975 T AT00912975 T AT 00912975T AT 00912975 T AT00912975 T AT 00912975T AT E402267 T1 ATE402267 T1 AT E402267T1
- Authority
- AT
- Austria
- Prior art keywords
- monoclonal antibody
- monoclonal antibodies
- producing monoclonal
- hybridoma
- producing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8792999 | 1999-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402267T1 true ATE402267T1 (de) | 2008-08-15 |
Family
ID=13928616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00912975T ATE402267T1 (de) | 1999-03-30 | 2000-03-30 | Verfahren zur herstellung von monoklonalen antikörpern |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8236530B2 (de) |
| EP (1) | EP1167537B1 (de) |
| AT (1) | ATE402267T1 (de) |
| AU (1) | AU754808B2 (de) |
| CA (1) | CA2368734C (de) |
| DE (1) | DE60039596D1 (de) |
| DK (1) | DK1167537T3 (de) |
| WO (1) | WO2000058499A1 (de) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067144B2 (en) | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US7312044B2 (en) | 2003-03-07 | 2007-12-25 | The Trustees Of Columbia University In The City Of New York | Type 1 ryanodine receptor-based methods |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
| PL207087B1 (pl) | 2001-04-26 | 2010-10-29 | Biogen | Przeciwciało, które wiąże się swoiście z białkiem Cripto, zawierająca je kompozycja farmaceutyczna i zastosowanie przeciwciała |
| US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| EP3539981A1 (de) * | 2006-09-10 | 2019-09-18 | Glycotope GmbH | Verwendung von menschlichen zellen myeloischen leukämieursprungs zur expression von antikörpern |
| CN101588817B (zh) * | 2006-09-10 | 2013-06-12 | 葛莱高托普有限公司 | 骨髓白血病来源的细胞在抗体表达中的用途 |
| AU2013203482B2 (en) * | 2006-09-10 | 2015-08-27 | Glycotope Gmbh | Fully human high yield production system for improved antibodies and proteins |
| EP1911766A1 (de) * | 2006-10-13 | 2008-04-16 | Glycotope Gmbh | Verwendung aus myeloischer Leukämie stammender humaner Zellen für die Exprimierung von Antikörpern |
| US20120282245A1 (en) | 2006-10-03 | 2012-11-08 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
| PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| MX2009008430A (es) | 2007-02-09 | 2009-10-28 | Genentech Inc | Anticuerpos anti-robo4 y sus usos. |
| EP2134855A4 (de) | 2007-03-12 | 2011-01-05 | Dana Farber Cancer Inst Inc | Verwendungen von fanci und fanci modulierenden agentien bei prognose, diagnose und krebstherapie |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| RU2536941C2 (ru) | 2009-06-10 | 2014-12-27 | Стефен Саниг Ресерч Инститьют Лтд. | Способы получения клеток, проявляющих фенотипическую пластичность |
| TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| CA2772715C (en) | 2009-09-02 | 2019-03-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
| WO2011071577A1 (en) | 2009-12-11 | 2011-06-16 | Genentech, Inc. | Anti-vegf-c antibodies and methods using same |
| BR112012013093A2 (pt) | 2009-12-21 | 2017-12-12 | Genentech Inc | ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável |
| DK2625197T3 (en) | 2010-10-05 | 2016-10-03 | Genentech Inc | Smoothened MUTANT AND METHODS OF USING THE SAME |
| ES2686313T3 (es) | 2011-08-22 | 2018-10-17 | Glycotope Gmbh | Microorganismos que portan un antígeno tumoral |
| MX369671B (es) | 2013-03-13 | 2019-11-15 | Genentech Inc | Formulaciones con oxidacion reducida. |
| AR095399A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida, método |
| CN110538322A (zh) | 2013-03-13 | 2019-12-06 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
| RU2707550C2 (ru) | 2013-03-13 | 2019-11-27 | Дженентек, Инк. | Составы со сниженным окислением |
| AR095398A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida |
| AU2014233393B2 (en) | 2013-03-15 | 2020-05-28 | Genentech, Inc. | Cell culture compositions with antioxidants and methods for polypeptide production |
| JP2016513478A (ja) | 2013-03-15 | 2016-05-16 | ジェネンテック， インコーポレイテッド | 細胞培養培地及び抗体を産生する方法 |
| MY175472A (en) | 2013-09-27 | 2020-06-29 | Genentech Inc | Anti-pdl1 antibody formulations |
| WO2015095423A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| JP2017507900A (ja) | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| AU2014364593A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody |
| ES2694857T3 (es) | 2014-02-04 | 2018-12-27 | Genentech, Inc. | Smoothened mutante y métodos de uso de la misma |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| CN106794247B (zh) | 2014-09-15 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
| SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| EP3253784B1 (de) | 2015-02-04 | 2020-05-06 | Genentech, Inc. | Smoothened-mutant und verfahren zur verwendung davon |
| KR102689256B1 (ko) | 2015-06-17 | 2024-07-30 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법 |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| CN115400220A (zh) | 2015-12-30 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 减少聚山梨酯降解的制剂 |
| JP7046814B2 (ja) | 2015-12-30 | 2022-04-04 | ジェネンテック， インコーポレイテッド | タンパク質製剤のためのトリプトファン誘導体の使用 |
| KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| EP3411396A1 (de) | 2016-02-04 | 2018-12-12 | Curis, Inc. | Smoothened-mutant und verfahren zur verwendung davon |
| US11767362B1 (en) | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
| WO2018029124A1 (en) | 2016-08-08 | 2018-02-15 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| MY205645A (en) | 2018-06-23 | 2024-11-02 | Genentech Inc | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| WO2020018789A1 (en) | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
| KR102898177B1 (ko) | 2018-08-08 | 2025-12-10 | 제넨테크, 인크. | 단백질 제제를 위한 트립토판 유도체 및 l-메티오닌의 용도 |
| KR102739487B1 (ko) | 2018-09-21 | 2024-12-10 | 제넨테크, 인크. | 3중-음성 유방암에 대한 진단 방법 |
| AU2021293038A1 (en) | 2020-06-16 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating triple-negative breast cancer |
| TW202517141A (zh) | 2023-07-13 | 2025-05-01 | 新加坡商蜂鳥生物科技私人有限公司 | 生產抗體的方法 |
| WO2025012473A1 (en) | 2023-07-13 | 2025-01-16 | Hummingbird Bioscience Pte. Ltd. | Methods for antibody production |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) * | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6475787B1 (en) * | 1989-07-28 | 2002-11-05 | Wyeth | Method for producing monoclonal antibodies |
| WO1993012227A1 (en) * | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
-
2000
- 2000-03-30 CA CA002368734A patent/CA2368734C/en not_active Expired - Lifetime
- 2000-03-30 AU AU34563/00A patent/AU754808B2/en not_active Expired
- 2000-03-30 DK DK00912975T patent/DK1167537T3/da active
- 2000-03-30 EP EP00912975A patent/EP1167537B1/de not_active Expired - Lifetime
- 2000-03-30 DE DE60039596T patent/DE60039596D1/de not_active Expired - Lifetime
- 2000-03-30 WO PCT/JP2000/002022 patent/WO2000058499A1/ja not_active Ceased
- 2000-03-30 AT AT00912975T patent/ATE402267T1/de not_active IP Right Cessation
-
2005
- 2005-09-28 US US11/238,983 patent/US8236530B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU3456300A (en) | 2000-10-16 |
| US8236530B2 (en) | 2012-08-07 |
| AU754808B2 (en) | 2002-11-28 |
| US20060059575A1 (en) | 2006-03-16 |
| EP1167537B1 (de) | 2008-07-23 |
| DE60039596D1 (de) | 2008-09-04 |
| CA2368734C (en) | 2005-08-23 |
| WO2000058499A1 (fr) | 2000-10-05 |
| DK1167537T3 (da) | 2008-11-10 |
| EP1167537A1 (de) | 2002-01-02 |
| CA2368734A1 (en) | 2000-10-05 |
| EP1167537A4 (de) | 2005-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE402267T1 (de) | Verfahren zur herstellung von monoklonalen antikörpern | |
| NZ324076A (en) | A composition comprising an immunoglobulin having an affinity constant for binding to predetermined human antigen and transgenic non-human animals capable of producing heterologous antibodies | |
| DE602004023965D1 (de) | Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen | |
| ATE313633T1 (de) | Expressionsvektoren die für bispezifische proteine kodieren, und verfahren zur herstellung von biologisch-aktiven bispezifischen fusionsproteine in zellen von säugertieren | |
| DE69000338D1 (de) | Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern. | |
| NL300335I2 (nl) | Menselijke monoklonale antilichamen tegen epidermale groeifactorreceptor | |
| DE59007589D1 (de) | Verfahren zur Herstellung hetero-bispezifischer Antikörper. | |
| DE602004002275D1 (de) | Verfahren zur herstellung rekombinanterpolyklonaler proteine | |
| DK0920505T3 (da) | Pattedyrcelleoverfladeantigener og tilhörende reagenser | |
| DE3278203D1 (en) | Monoclonal antibodies specific for the human transferrin receptor glycoprotein | |
| ATE476504T1 (de) | Verfahren zur herstellung von protein- bibliotheken und zur selektion von proteinen daraus | |
| LU91756I2 (fr) | Denosumab | |
| DK0419858T3 (da) | Hunde-muse-heterohybridom og genfragment, som koder for den konstante region af hundeimmunglobuliner | |
| RU94045919A (ru) | Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция | |
| DE60014124D1 (de) | Antikörper, die spezifisch für fullerene sind | |
| ATE135041T1 (de) | Verfahren zur herstellung von faktorabhängigen menschlichen b-zellinien | |
| DE3582358D1 (de) | Monoklonaler antikoerper und verfahren zur quantitativen bestimmung von immunoglobulinen mittels dieses antikoerpers. | |
| DE3581288D1 (de) | Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen. | |
| ATE337395T1 (de) | Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper | |
| ATE160288T1 (de) | Antikörper, ihre herstellung und verwendung | |
| PT733643E (pt) | Polipeptido proteico membranar possuindo funcao de suporte do crescimento de pre-celulas b e gene para este | |
| DE3783002D1 (de) | Neue monoklonale antikoerper gegen ifn-omega, verfahren zu ihrer herstellung und deren verwendung zur reinigung sowie zum nachweis von ifn-omega. | |
| EP0556320A4 (en) | Monoclonal antibodies to hepatitis c virus and method for using same | |
| Nishinaka et al. | Production of chicken monoclonal antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |